Log in

ASX:NYRNyrada Stock Price, Forecast & News

A$0.16
-0.01 (-5.71 %)
(As of 05/13/2020)
Add
Compare
Today's Range
A$0.17
Now: A$0.17
A$0.17
50-Day Range N/A
52-Week Range
A$0.11
Now: A$0.17
A$0.31
Volume65,000 shs
Average VolumeN/A
Market Capitalization$18.05 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Nyrada Inc., a pre-clinical stage drug development company, engages in the development of small molecule drugs for cardiovascular, neurodegenerative, and chronic inflammatory diseases. Its products in drug development stage include PCSK9 inhibitor for the treatment of high blood LDL-cholesterol levels in patients poorly responsive to or unable to take statin drugs; a neuroprotectant drug to reduce the impact of long-term disability in patients with ischaemic stroke and traumatic brain injury; a drug to treat pain associated with peripheral nerve damage; and a drug to treat autoimmune diseases, such as psoriasis. The company was founded in 2017 and is based in Gordon, Australia.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.60 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone61 2 9053 1990

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$486,338.00
Cash FlowA$0.01 per share
Book ValueA($0.44) per share

Profitability

Miscellaneous

EmployeesN/A
Market Cap$18.05 million
Next Earnings DateN/A
OptionableNot Optionable

Receive NYR News and Ratings via Email

Sign-up to receive the latest news and ratings for NYR and its competitors with MarketBeat's FREE daily newsletter.

Nyrada (ASX:NYR) Frequently Asked Questions

Has Nyrada been receiving favorable news coverage?

News coverage about NYR stock has trended very negative this week, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Nyrada earned a coverage optimism score of -3.0 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news aboutNyrada.

Who are some of Nyrada's key competitors?

Who are Nyrada's key executives?

Nyrada's management team includes the following people:
  • Mr. James Bonnar, Chief Exec. Officer
  • Dr. Graham Edmund Kelly, Founder, Pres & Non-Independent Exec. Director (Age 75)
  • Mr. Cameron Jones, Chief Financial Officer
  • Mr. Benjamin Evison, Chief Scientific Officer
  • Mr. Mark Waring, Sr. VP of US Operations

What is Nyrada's stock symbol?

Nyrada trades on the ASX under the ticker symbol "NYR."

What is Nyrada's stock price today?

One share of NYR stock can currently be purchased for approximately A$0.17.

How big of a company is Nyrada?

Nyrada has a market capitalization of $18.05 million and generates $486,338.00 in revenue each year.

What is Nyrada's official website?

The official website for Nyrada is www.nyrada.com.

How can I contact Nyrada?

The company can be reached via phone at 61 2 9053 1990.

This page was last updated on 6/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.